N-(4-叔丁基苯基)-4-(3-氯吡啶-2-基)苯甲酰胺 | 717115-97-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-叔丁基苯基)-4-(3-氯吡啶-2-基)苯甲酰胺
• 英文名称: N-(4-tert-butylphenyl)-4-(3-chloro-2-pyridinyl)benzamide
• 英文别名: N-(4-tert-butyl-phenyl)-4-(3-chloro-pyridin-2-yl)-benzamide；N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)benzamide
• CAS: 717115-97-4
• 化学式: C₂₂H₂₁ClN₂O
• 分子量: 364.875
• InChiKey: QCRWGKKDPMVPSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,3-二氯吡啶 在 四(三苯基膦)钯 PS-DCC 、 sodium carbonate 、 1-羟基苯并三唑 、 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 、 水 、 乙腈 为溶剂， 反应 21.0h， 生成 N-(4-叔丁基苯基)-4-(3-氯吡啶-2-基)苯甲酰胺
  参考文献：
  名称：

  Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor

  摘要：

  本发明涉及一种化合物（I）的公式，这些化合物是新型VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁或膀胱过度活动。

  公开号：

  US20050085512A1

文献信息

• From arylureas to biarylamides to aminoquinazolines: Discovery of a novel, potent TRPV1 antagonist
  作者：Xiaozhang Zheng、Kevin J. Hodgetts、Harry Brielmann、Alan Hutchison、Frank Burkamp、A. Brian Jones、Peter Blurton、Robert Clarkson、Jayaraman Chandrasekhar、Rajagopal Bakthavatchalam、Stéphane De Lombaert、Marci Crandall、Daniel Cortright、Charles A. Blum

  DOI：10.1016/j.bmcl.2006.07.010

  日期：2006.10

  Bioisosteric replacement of piperazine with an aryl ring in lead VR1 antagonist 1 led to the biarylamide series. The development of B-ring SAR led to the conformationally constrained analog 70. The resulting aminoquinazoline 70 represents a novel VR1 antagonist with improved in vitro potency and oral bioavailability vs the analogous compounds from the lead series.

  铅VR1拮抗剂1中芳基环的哌嗪生物等位取代导致了联芳基酰胺系列的产生。B环SAR的发展导致构象受限的类似物70。所得氨基喹唑啉70代表一种新型VR1拮抗剂，与先导系列的类似化合物相比，具有更高的体外效价和口服生物利用度。
• Substituted biphenyl-4-carboxylic acid arylamide analogues
  申请人：Bakthavatchalam Rajagopal

  公开号：US20060100245A1

  公开（公告）日：2006-05-11

  Substituted biphenyl-4-carboxylic acid arylamide analogues capable of modulating receptor activity, are provided. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了能够调节受体活性的取代联苯-4-羧酸芳香酰胺类似物。这样的配体可以用于体内或体外调节受体活性，并且在治疗与人类、家畜伴侣动物和家畜动物中的受体激活有关的疼痛和其他疾病方面特别有用。提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的配体使用方法。
• Amides that inhibit vanilloid receptor subtype 1 (VR1)
  申请人：Lee Chih-Hung

  公开号：US20060122231A1

  公开（公告）日：2006-06-08

  The present invention relates to compounds of formula (I) that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

  本发明涉及公式（I）的化合物，它们是新型的VR1拮抗剂，可用于治疗疼痛、炎症性热痛敏、尿失禁或膀胱过度活动。
• Amide compounds as ion channel ligands and uses thereof
  申请人：Kelly Michael G.

  公开号：US20080200524A1

  公开（公告）日：2008-08-21

  Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  披露了一些化合物，其化学式表示为以下形式：这些化合物可以制备成药物组合物，并可用于预防和治疗哺乳动物包括人类的各种情况，例如但不限于疼痛，炎症，创伤性损伤等。
• Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands
  作者：Hyeung-geun Park、Ji-yeon Choi、Mi-hyun Kim、Sea-hoon Choi、Mi-kyung Park、Jihye Lee、Young-Ger Suh、Hawon Cho、Uhtaek Oh、Hee-Doo Kim、Yung Hyup Joo、Song Seok Shin、Jin Kwan Kim、Yeon Su Jeong、Hyun-Ju Koh、Young-Ho Park、Sang-sup Jew

  DOI：10.1016/j.bmcl.2004.11.033

  日期：2005.2

  Seventeen biarylcarboxybenzamide derivatives were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor (VR1) in rat DRG neurons. The replacement of the piperazine moiety of the lead compound I with phenyl ring showed quite enhanced antagonistic activity. Among the prepared derivatives, N-(4-tert-butylphenyl)-4-pyridine-2-yl-benzamide (2, IC50 = 31 nM) and N-(4-tet-t-butylphenyl)-4-(3-methylpyridine-2-yl)benzamide (3g, IC50 = 31 nM), showed 5-fold higher antagonistic activity than 1 in Ca-45 (2+)-influx assay. (C) 2004 Elsevier Ltd. All rights reserved.